This recombinant monoclonal antibody is developed as a research-grade biosimilar to Vunakizumab, targeting interleukin-17A (IL-17A), a pro-inflammatory cytokine central to immune responses and inflammatory pathology. IL-17A is primarily produced by Th17 cells and plays a critical role in host defense against extracellular pathogens while also driving chronic inflammation when dysregulated. Elevated IL-17A signaling is implicated in numerous autoimmune and inflammatory conditions, including psoriasis, rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel disease, making it a valuable therapeutic target for investigation.
Vunakizumab is a humanized IgG monoclonal antibody designed to neutralize IL-17A with high specificity and affinity. This biosimilar provides researchers with a cost-effective tool for studying IL-17A-mediated inflammatory pathways, investigating disease mechanisms in autoimmune disorders, and evaluating potential therapeutic interventions in preclinical models. The antibody is suitable for experiments examining cytokine neutralization, immune cell function, and inflammatory signaling cascades in various research contexts.
Email: support@cusabio.com
Distributors Worldwide